U.S. markets close in 2 hours 37 minutes
  • S&P 500

    3,950.81
    -138.04 (-3.38%)
     
  • Dow 30

    31,694.01
    -960.58 (-2.94%)
     
  • Nasdaq

    11,502.84
    -481.68 (-4.02%)
     
  • Russell 2000

    1,787.19
    -53.11 (-2.89%)
     
  • Crude Oil

    109.69
    -2.71 (-2.41%)
     
  • Gold

    1,818.50
    -0.40 (-0.02%)
     
  • Silver

    21.56
    -0.19 (-0.87%)
     
  • EUR/USD

    1.0483
    -0.0072 (-0.68%)
     
  • 10-Yr Bond

    2.9040
    -0.0640 (-2.16%)
     
  • GBP/USD

    1.2368
    -0.0124 (-1.00%)
     
  • USD/JPY

    128.2880
    -1.0700 (-0.83%)
     
  • BTC-USD

    29,077.50
    -1,123.79 (-3.72%)
     
  • CMC Crypto 200

    650.02
    -20.66 (-3.08%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

2 Top Healthcare Stocks Ready for a Bull Run

·4 min read
2 Top Healthcare Stocks Ready for a Bull Run
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer (NYSE: PFE) has (at least) two major revenue drivers that could power its share price higher: Its coronavirus vaccine, Comirnaty, and its new antiviral treatment for COVID-19, Paxlovid. Comirnaty is responsible for a sizable portion of its trailing revenue of $69.3 billion, and it's doubtlessly why the pharma's quarterly sales have grown by 134.4% as of Q3 in 2021. Pfizer also plans to invest more in the mRNA technology behind Comirnaty to build out its pipeline of vaccines and therapeutics.